Comparison of the I Kr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 467-478

  Nalos, L ^a   Varkevisser, R ^a   Jonsson, M K B ^a   Houtman, M J C ^a   Beekman, J D ^a   Van Der Nagel, R ^a   Thomsen, M B ^a,e   Duker, G ^b   Sartipy, P ^c   De Boer, T P ^a   Peschar, M ^d   Rook, M B ^a   Van Veen, T A B ^a   Van Der Heyden, M A G ^a   Vos, Marc A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

^c Cellartis AB   (Sweden)

^d Department of Toxicology ^*  (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

beat to beat variability of repolarization; cardiac safety pharmacology; chronic AV block dog; dofetilide; human embryonic stem cell derived cardiomyocytes; isolated cardiomyocytes; methoxamine sensitized rabbit; moxifloxacin

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; DOFETILIDE; MOXIFLOXACIN; ANTIARRHYTHMIC AGENT; HETEROCYCLIC COMPOUND; METHOXAMINE; PHENETHYLAMINE DERIVATIVE; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLETE HEART BLOCK; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DOG; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART MUSCLE CELL; HEART PROARRHYTHMIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SENSITIVITY AND SPECIFICITY; TORSADE DES POINTES; ACTION POTENTIAL; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; EMBRYONIC STEM CELL; FEMALE; HEART; HEART BLOCK; HEART VENTRICLE REMODELING; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; AZA COMPOUNDS; CELL LINE; DISEASE MODELS, ANIMAL; DOGS; EMBRYONIC STEM CELLS; FEMALE; HEART; HEART BLOCK; HUMANS; METHOXAMINE; MYOCYTES, CARDIAC; PHENETHYLAMINES; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; QUINOLINES; RABBITS; SULFONAMIDES; TORSADES DE POINTES; VENTRICULAR REMODELING;

EID: 83755172797     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01558.x     Document Type: Article

References (52)

1. Abi-Gerges N, Valentin JP, Pollard CE, (2010). Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential. Br J Pharmacol 159: 77-92.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164: S1-S324.
3. + channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 147: 905-916.
4. Anderson ME, Mazur A, Yang T, Roden DM, (2001). Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 296: 806-810. (Pubitemid 32187351)
5. Andriole VT, Haverstock DC, Choudhri SH, (2005). Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 28: 443-452. (Pubitemid 40733730)
6. + current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol 55: 801-809.
7. Badshah A, Janjua M, Younas F, Halabi AR, Cotant JF, (2009). Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug. Am J Med Sci 338: 164-166.
8. Bányász T, Horváth B, Virág L, Bárándi L, Szentandrássy N, Harmati G, et al,. (2009). Reverse rate dependency is an intrinsic property of canine cardiac preparations. Cardiovasc Res 84: 237-244.
9. Biliczki P, Virág L, Iost N, Papp JG, Varró A, (2002). Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br J Pharmacol 137: 361-368.
10. Carlsson L, (2008). The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacol Ther 119: 160-167.
11. Carlsson L, Almgren O, Duker G, (1990). QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 16: 276-285. (Pubitemid 20222650)
12. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G, (1993). Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 27: 2186-2193. (Pubitemid 24034733)
13. Carlsson L, Andersson B, Linhardt G, Löfberg L, (2009). Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. J Cardiovasc Pharmacol 54: 82-89.
14. Caspi O, Itzhaki I, Arbel G, Kehat I, Gepstien A, Huber I, et al,. (2009). In Vitro Electrophysiological Drug Testing using Human Embryonic Stem Cell Derived Cardiomyocytes. Stem Cells Dev 18: 161-172.
15. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, et al,. (2005). QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 146: 792-799. (Pubitemid 41622245)
16. Chiba K, Sugiyama A, Hagiwara T, Takahashi S, Takasuna K, Hashimoto K, (2004). In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol 486: 189-200. (Pubitemid 38224530)
17. Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalsky SF, et al,. (2004). Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 38: 749-754. (Pubitemid 38509046)
18. Gintant G, (2011). An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129: 109-119.
19. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ, (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 93: 32-39. (Pubitemid 36859038)
20. Hinterseer M, Thomsen MB, Beckmann BM, Pfeufer A, Schimpf R, Wichmann HE, et al,. (2008). Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. Eur Heart J 29: 185-190.
21. Hondeghem LM, Carlsson L, Duker G, (2001). Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic. Circulation 103: 2004-2013. (Pubitemid 32322230)
22. ICH Harmonized Tripartite Guideline E14 (2005). The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Available at:.
23. ICH Harmonized Tripartite Guideline S7B (2005). The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Available at:.
24. Johnson DM, Heijman J, Pollard CE, Valentin JP, Crijns HJ, Abi-Gerges N, et al,. (2010). I(Ks) restricts excessive beat-to-beat variability of repolarization during beta-adrenergic receptor stimulation. J Mol Cell Cardiol 48: 122-130.
25. Jonsson MK, Duker G, Tropp C, Anderson B, Sartipy P, Vos MA, et al,. (2010). Quantified Proarrhythmic Potential of Selected Human Embryonic Stem Cell-derived Cardiomyocytes. Stem Cell Res 4: 189-200.
26. + channel HERG. Mol Pharmacol 59: 122-126. (Pubitemid 32043093)
27. Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, Valentin JP, (2006). A rabbit langendorff heart proarrhythmia model: predictive value for clinical identification of torsades de pointes. Br J Pharmacol 149: 845-860. (Pubitemid 44851709)
28. Martin R, McDermott J, Salmen H, Palmatier J, Cox B, Gintant GA, (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43: 369-379. (Pubitemid 38270603)
29. Matthys G, Park JW, McGuire S, Wire MB, Zhang J, Bowen C, et al,. (2010). Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol 70: 24-33.
30. Oros A, Beekman JD, Vos MA, (2008). The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther 119: 168-178.
31. Pastore JM, Rosenbaum DS, (2000). Role of structural barriers in the mechanism of alternans-induced reentry. Circ Res 87: 1157-1163.
32. Pedersen HS, Elming H, Seibaek M, Burchardt H, Brendorp B, Torp-Pedersen C, et al,. DIAMOND Study Group (2007). Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol 100: 876-880. (Pubitemid 47268281)
33. Pekkanen-Mattila M, Chapman H, Kerkela E, Suuronen R, Skottman H, Koivisto A-P, et al,. (2010). Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype. Exp Biol Med 235: 522-530.
34. Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A, (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 61: 277-286.
35. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F, (2010). Antimicrobials and the risk of Torsade de Pointes. The contribution from data mining of the US FDA adverse event reporting system. Drug Saf 33: 303-314.
36. Roden DM, (1998). Mechanisms and management of proarrhythmia. Am J Cardiol 82: 491-571.
37. Roden DM, Hoffman BF, (1985). Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje Fibers. Circ Res 56: 857-867. (Pubitemid 15231509)
38. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
39. Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA, (2008). Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 83: 153-159.
40. Sasse M, Paul T, Bergmann P, Kallfelz HC, (1998). Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate. Pacing Clin Electrophysiol 21: 1164-1166. (Pubitemid 28225876)
41. Schoenmakers M, Ramakers C, van Opstal JM, Leunissen JD, Londoño C, Vos MA, (2003). Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 59: 351-359. (Pubitemid 37272029)
42. Sherazi S, DiSalle M, Daubert JP, Shah AH, (2008). Moxifloxacin induced Torsade de Pointes. Cardiol J 15: 71-73.
43. Stass H, Dalhoff A, Kubitza D, Schühly U, (1998). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42: 2060-2065. (Pubitemid 28363093)
44. Synnergren J, Akesson K, Dahlenborg K, Vidarsson H, Améen C, Steel D, et al,. (2008). Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells 26: 1831-1840.
45. Takahara A, Nakamura Y, Sugiyama A, (2008). Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone. Eur J Pharmacol 596: 127-131.
46. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, et al,. (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110: 2453-2459. (Pubitemid 39407353)
47. Thomsen MB, Beekman HDM, Atteveld N, Takahara A, Sugiyama A, Chiba K, et al,. (2006). No proarrhythmic activity of the antibiotics moxifloxacin and azythromycin in anesthetized dogs with chronic AV-block. Br J Pharmacol 149: 1039-1048. (Pubitemid 44950807)
48. Thomsen MB, Oros A, Schoenmakers M, van Opstal JM, Maas JN, Beekman JD, et al,. (2007). Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 73: 521-530. (Pubitemid 46073954)
49. Van de Water A, Verheyen J, Xhonneux R, Reneman RS, (1989). An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 22: 207-217. (Pubitemid 19275446)
50. Van Opstal JM, Leunissen JD, Wellens HJ, Vos MA, (2001). Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. Eur J Pharmacol 412: 67-76. (Pubitemid 32149771)
51. Vos MA, (2008). Literature based evaluation of four hard end-points models for assessing drug induced Torsades de Pointes liability. Br J Pharmacol 154: 1523-1527.
52. Zeitlinger M, Sauermann R, Fille M, Hausdorfer J, Leitner I, Müller M, (2008). Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother 61: 561-567. (Pubitemid 351321128)